Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Johns Hopkins Medicine
Office of Corporate Communications
U.S. Media Contact: Gary Stephenson
International Media Contact: Emilio Williams
September 28, 2004
After an extensive international search, Ian McNiece, Ph.D., has been selected to chair the new Division of Biomedical Sciences, Johns Hopkins in Singapore (known as DJHS). Since 2003, McNiece has been based in Baltimore, Maryland, where he is Professor of Oncology, and also serves as Director of the Graft Engineering Laboratory at Johns Hopkins Medicine. DJHS is the first academic division of Johns Hopkins School of Medicine based outside Baltimore, Maryland. DJHS will be located in Biopolis.
DJHS has recently embarked on an ambitious growth plan which will include 12 full-time Johns Hopkins faculty based in Singapore to lead training and research initiatives in biomedical science disciplines such as immunology, cellular therapy, cancer biology and experimental therapeutics. Within two years, DJHS plans to build a staff of 150 research professionals. The new Johns Hopkins division will also offer graduate training (Ph.D. programs) in basic and clinical research to Singaporeans and other Southeast nationals. The Ph.D. training conducted in Singapore and Baltimore will lead to either a Hopkins Ph.D. or National University of Singapore (NUS) Ph.D. degree.
“With this appointment, we are bringing Hopkins’ relationship with the Singaporean scientific community to a new and higher level” said Edward D. Miller, M.D., Dean and CEO of Johns Hopkins Medicine. The relationship of Johns Hopkins with the scientific community of Singapore started in 1998. “Now that we have a full-fledged division of our School of Medicine, we felt that Ian was the best candidate to bring the highest standards of Hopkins research to this new endeavor. We felt that his experience in translational research will be key to make the venture succeed.”
“It is an honor for me to be part of the vision to advance the biomedical sciences in Singapore,” added McNiece. “I believe that we have the opportunity not only to attract leading scientific talent in the region, but also to develop a new generation of scientists that will continue our quest for lifesaving discoveries”
An Australian by birth, McNiece is internationally renowned for his contributions as a researcher in stem cell biology and clinical marrow and stem cell transplantation. He trained at Melbourne University in Australia, where he received his B.Sc. in Biochemistry (1979), an M.Sc. (1981) and Ph.D. (1986) degrees in Physiology. He completed his thesis work at the Peter MacCallum Cancer Institute in Melbourne. McNiece subsequently came to the United States as a postdoctoral fellow at the University of Virginia.
In 1988, he joined Amgen,Inc., Thousand Oaks, California, as a Research Scientist and became Laboratory Head in the Department of Developmental Hematology in 1994. In 1995, he was appointed to head the Amgen Central Laboratory at Saint Luc University Hospital in Belgium. Before joining Johns Hopkins Medicine, as a professor, McNiece worked at the University of Colorado Health Science Center where he was Director of Research for the Bone Marrow Transplant Program and Director of the Stem Cell Biology Program.